Drug firm Suven Life Sciences today announced initiation of phase 1 clinical trial and first dosing of a chemical entity intended for the treatment of major depressive disorder. In a BSE filing, Suven Life Sciences said its NCESUVN- 911, a “novel chemical entity intended for the treatment of major depressive disorder (MDD) has initiated Phase 1 development and first dosing… and the topline results from the study is expected during the quarter Jan-March 2018”.
Suven Life CEO Venkat Jasti said: “Progression of SUVN- 911 into phase 1 clinical development is a significant achievement in enhancing our clinical pipeline beyond Dementia into mental illness arena, Major Depressive Disorder (MDD).”
Suven Life said the global antidepressant market is valued over $20 billion. Suven Life Sciences shares were trading 1.01 per cent up at Rs 75.80 on BSE in morning trade.